Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
These nutraceutical products contain 100 per cent natural marine bioactive ingredients from selected seaweeds, which are commonly available in the Indian coastal waters
ICAR-Central Marine Fisheries Research Institute (CMFRI) has commercialised patent-protected technologies of two seaweed-based nutraceutical products: one to boost anti-viral immunity and the other to combat high cholesterol or dyslipidemia.
Dr A Gopalakrishnan, Director of CMFRI signed a license agreement with Joby George, Managing Partner of Pioneer Pharmaceuticals Ltd, a wellness and pharmaceutical company based in Kochi for commercial production and marketing of these products.
Bioactive pharmacophore leads from seaweeds were used to develop these two nutraceutical products, which are a 100 per cent natural blend of highly nutritious bioactive ingredients extracted with eco-friendly ‘green’ technology, said Dr A Gopalakrishnan.
These nutraceutical products contain 100 per cent natural marine bioactive ingredients from selected seaweeds, which are commonly available in the Indian coastal waters.
Besides these two products, the institute has successfully brought out nutraceuticals targeting a range of lifestyle diseases, such as type-2 diabetes, arthritis, hypertension, hypothyroidism, osteoporosis and fatty liver.
These products would be made available in the market within a six-month time frame by Pioneer Pharmaceuticals.